Female Rats Need 10× Higher Doses of a Ghrelin Drug for the Same Gut-Moving Effect as Males
A ghrelin receptor agonist enhanced colorectal motility in both male and female rats, but females required approximately 10-fold higher doses — likely due to lower ghrelin receptor expression in the female lumbosacral spinal cord.
Quick Facts
What This Study Found
The ghrelin agonist RQ-00538053 enhanced colorectal motility in female rats but required ~10× higher doses than in males, correlating with lower ghrelin receptor expression in the female lumbosacral spinal cord.
Key Numbers
Approximately 10-fold higher doses needed in female vs. male rats for similar colorectal motility responses; tested via both intravenous and intrathecal routes.
How They Did This
Pharmacological study comparing intravenous and intrathecal (lumbosacral spinal cord) administration of ghrelin agonist RQ-00538053 in male and female Sprague-Dawley rats, with RT-qPCR analysis of ghrelin receptor expression.
Why This Research Matters
Constipation disproportionately affects women. If ghrelin-based drugs for gut motility require sex-specific dosing, clinical trials and eventual prescribing must account for this biological difference — otherwise, women may be systematically underdosed.
The Bigger Picture
Sex differences in drug response are increasingly recognized but still underappreciated in drug development. This study adds ghrelin receptor agonists to the growing list of therapeutics where biological sex significantly affects efficacy — reinforcing the need for sex-stratified clinical trials in gut motility disorders.
What This Study Doesn't Tell Us
Animal study in rats — sex differences in ghrelin receptor expression may differ in humans. Only one ghrelin agonist tested. Sample size not specified in abstract. The mechanism is partially explained (receptor expression) but other factors (hormonal, metabolic) may contribute.
Questions This Raises
- ?Do human females also have lower ghrelin receptor expression in the lumbosacral spinal cord compared to males?
- ?Could estrogen or other sex hormones modulate ghrelin receptor expression in the spinal cord?
- ?Would sex-specific dosing of ghrelin agonists translate to better constipation outcomes in clinical trials?
Trust & Context
- Key Stat:
- ~10× dose difference Female rats required approximately tenfold higher doses of ghrelin agonist for equivalent colorectal motility response
- Evidence Grade:
- Moderate evidence — well-designed animal pharmacology study with mechanistic insight (receptor expression data). However, translation to human dosing is uncertain.
- Study Age:
- Published in 2024. Addresses an emerging area of sex-specific pharmacology in gut peptide therapeutics.
- Original Title:
- Sexual dimorphism in prokinetic effects of a ghrelin agonist acting through the lumbosacral defecation center in rats.
- Published In:
- The journal of physiological sciences : JPS, 74(1), 54 (2024)
- Authors:
- Tsukamoto, Shumpei, Sawamura, Tomoya, Yuki, Natsufu, Horii, Kazuhiro, Horii, Yuuki, Homma, Takeshi, Saito, Shouichiro, Shiina, Takahiko, Shimizu, Yasutake
- Database ID:
- RPEP-09412
Evidence Hierarchy
Frequently Asked Questions
Why would a ghrelin drug work differently in males and females?
This study found that female rats have fewer ghrelin receptors in the part of the spinal cord that controls bowel movements. With fewer receptors to bind to, the drug needs a higher dose to trigger the same gut-stimulating response. This is a biological sex difference, not just a body size issue.
Could this affect future constipation medications?
Yes — if ghrelin-based drugs are developed for constipation (which disproportionately affects women), doctors may need to prescribe different doses for men and women. Without sex-specific dosing, women might not get enough drug to achieve the desired effect.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09412APA
Tsukamoto, Shumpei; Sawamura, Tomoya; Yuki, Natsufu; Horii, Kazuhiro; Horii, Yuuki; Homma, Takeshi; Saito, Shouichiro; Shiina, Takahiko; Shimizu, Yasutake. (2024). Sexual dimorphism in prokinetic effects of a ghrelin agonist acting through the lumbosacral defecation center in rats.. The journal of physiological sciences : JPS, 74(1), 54. https://doi.org/10.1186/s12576-024-00949-w
MLA
Tsukamoto, Shumpei, et al. "Sexual dimorphism in prokinetic effects of a ghrelin agonist acting through the lumbosacral defecation center in rats.." The journal of physiological sciences : JPS, 2024. https://doi.org/10.1186/s12576-024-00949-w
RethinkPeptides
RethinkPeptides Research Database. "Sexual dimorphism in prokinetic effects of a ghrelin agonist..." RPEP-09412. Retrieved from https://rethinkpeptides.com/research/tsukamoto-2024-sexual-dimorphism-in-prokinetic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.